Far upstream element binding protein 1: A commander of transcription, translation and beyond

Oncogene

Volumn 32, Issue 24, 2013, Pages 2907-2916

  Zhang, J ^a   Chen, Q M ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

cancer; FBP1; FUSE

Indexed keywords

CYCLOOXYGENASE 2; DNA BINDING PROTEIN; FAR UPSTREAM ELEMENT BINDING PROTEIN 1; MYC PROTEIN; NEUROMODULIN; PROTEIN P21; PROTEIN P27; RNA BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; APOPTOSIS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN IMMUNOPRECIPITATION; COMBINATORIAL CHEMISTRY; DNA BINDING; DNA DNA HYBRIDIZATION; DNA LIBRARY; DNA TRANSCRIPTION; GEL MOBILITY SHIFT ASSAY; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; RNA RNA HYBRIDIZATION; RNA TRANSLATION; TRANSCRIPTION REGULATION;

ANIMALS; DNA HELICASES; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; PROTEIN BIOSYNTHESIS; RNA-BINDING PROTEINS; TRANSCRIPTION, GENETIC;

HEPATITIS C VIRUS; HUMAN ENTEROVIRUS 71;

EID: 84879421217     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.350     Document Type: Review

References (99)

1. de Nigris F, Sica V, Herrmann J, Condorelli G, Chade AR, Tajana G et al. c-Myc oncoprotein: cell cycle-related events and new therapeutic challenges in cancer and cardiovascular diseases. Cell Cycle 2003; 2: 325-328.
2. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene 2008; 27: 6462-6472.
3. Levens D. Disentangling the MYC web. Proc Natl Acad Sci USA 2002; 99: 5757-5759.
4. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002; 2: 764-776.
5. Avigan MI, Strober B, Levens D. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 1990; 265: 18538-18545.
6. Duncan R, Bazar L, Michelotti G, Tomonaga T, Krutzsch H, Avigan M et al. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev 1994; 8: 465-480.
7. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A et al. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 2006; 25: 2119-2130.
8. Chien HL, Liao CL, Lin YL. FUSE binding protein 1 interacts with untranslated regions of Japanese encephalitis virus RNA and negatively regulates viral replication. J Virol 2011; 85: 4698-4706.
9. Irwin N, Baekelandt V, Goritchenko L, Benowitz LI. Identification of two proteins that bind to a pyrimidine-rich sequence in the 3'-untranslated region of GAP-43 mRNA. Nucleic Acids Res 1997; 25: 1281-1288.
10. Olanich ME, Moss BL, Piwnica-Worms D, Townsend RR, Weber JD. Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation. Oncogene 2011; 30: 77-86.
11. Zheng Y, Miskimins WK. Far upstream element binding protein 1 activates translation of p27Kip1 mRNA through its internal ribosomal entry site. Int J Biochem Cell Biol 2011; 43: 1641-1648.
12. Matsushita K, Tomonaga T, Shimada H, Shioya A, Higashi M, Matsubara H et al. An essential role of alternative splicing of c-myc suppressor FUSE-binding protein-interacting repressor in carcinogenesis. Cancer Res 2006; 66: 1409-1417.
13. Niforou KM, Anagnostopoulos AK, Vougas K, Kittas C, Gorgoulis VG, Tsangaris GT. The proteome profile of the human osteosarcoma U2OS cell line. Cancer Genomics Proteomics 2008; 5: 63-78.
14. Zhang L, Yang H, Xu J. Gene expression significance in personalized medicine of non-small-cell lung cancer and gene expression analyzing platforms. Curr Drug Metab 2011; 12: 455-459.
15. Zubaidah RM, Tan GS, Tan SB, Lim SG, Lin Q, Chung MC. 2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics 2008; 8: 5086-5096.
16. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD, Hruban RH et al. Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011; 333: 1453-1455.
17. Malz M, Weber A, Singer S, Riehmer V, Bissinger M, Riener MO et al. Over-expression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 2009; 50: 1130-1139.
18. Matsushita K, Tomonaga T, Kajiwara T, Shimada H, Itoga S, Hiwasa T et al. c-myc suppressor FBP-interacting repressor for cancer diagnosis and therapy. Front Biosci 2009; 14: 3401-3408.
19. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P et al. Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 2009; 50: 1121-1129.
20. Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH, Kang JW et al. Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet 2003; 34: 330-336.
21. Williams BY, Hamilton SL, Sarkar HK. The survival motor neuron protein interacts with the transactivator FUSE binding protein from human fetal brain. FEBS Lett 2000; 470: 207-210.
22. Bentley DL, Groudine M. A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells. Nature 1986; 321: 702-706.
23. Westin EH, Wong-Staal F, Gelmann EP, Dalla-Favera R, Papas TS, Lautenberger JA et al. Expression of cellular homologues of retroviral onc genes in human hematopoietic cells. Proc Natl Acad Sci USA 1982; 79: 2490-2494.
24. Bazar L, Harris V, Sunitha I, Hartmann D, Avigan M. A transactivator of c-myc is coordinately regulated with the proto-oncogene during cellular growth. Oncogene 1995; 10: 2229-2238.
25. Davis-Smyth T, Duncan RC, Zheng T, Michelotti G, Levens D. The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators. J Biol Chem 1996; 271: 31679-31687.
26. Michelotti GA, Michelotti EF, Pullner A, Duncan RC, Eick D, Levens D. Multiple single-stranded cis elements are associated with activated chromatin of the human c-myc gene in vivo. Mol Cell Biol 1996; 16: 2656-2669.
27. Duncan R, Collins I, Tomonaga T, Zhang T, Levens D. A unique transactivation sequence motif is found in the carboxyl-terminal domain of the single-strand-binding protein FBP. Mol Cell Biol 1996; 16: 2274-2282.
28. Valverde R, Edwards L, Regan L. Structure and function of KH domains. FEBS J 2008; 275: 2712-2726.
29. Braddock DT, Baber JL, Levens D, Clore GM. Molecular basis of sequence-specific single-stranded DNA recognition by KH domains: solution structure of a complex between hnRNP K KH3 and single-stranded DNA. EMBO J 2002; 21: 3476-3485.
30. He L, Liu J, Collins I, Sanford S, O'Connell B, Benham CJ et al. Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J 2000; 19: 1034-1044.
31. Liu J, Akoulitchev S, Weber A, Ge H, Chuikov S, Libutti D et al. Defective interplay of activators and repressors with TFIH in xeroderma pigmentosum. Cell 2001; 104: 353-363.
32. Giglia-Mari G, Coin F, Ranish JA, Hoogstraten D, Theil A, Wijgers N et al. A new, tenth subunit of TFIIH is responsible for the DNA repair syndrome trichothiody-strophy group A. Nat Genet 2004; 36: 714-719.
33. Tuteja N, Rahman K, Tuteja R, Falaschi A. Human DNA helicase V, a novel DNA unwinding enzyme from HeLa cells. Nucleic Acids Res 1993; 21: 2323-2329.
34. Vindigni A, Ochem A, Triolo G, Falaschi A. Identification of human DNA helicase V with the far upstream element-binding protein. Nucleic Acids Res 2001; 29: 1061-1067.
35. Costa M, Ochem A, Staub A, Falaschi A. Human DNA helicase VIII: a DNA and RNA helicase corresponding to the G3BP protein, an element of the ras transduction pathway. Nucleic Acids Res 1999; 27: 817-821.
36. Bouchireb N, Clark MS. Human FUSE binding protein 3 gene (FBP3). Map position 9q33-34.1. Chromosome Res 1999; 7: 577.
37. Gherzi R, Chen CY, Trabucchi M, Ramos A, Briata P. The role of KSRP in mRNA decay and microRNA precursor maturation. Wiley Interdiscip Rev RNA 2010; 1: 230-239.
38. Danckwardt S, Gantzert AS, Macher-Goeppinger S, Probst HC, Gentzel M, Wilm M et al. p38 MAPK controls prothrombin expression by regulated RNA 3' end processing. Mol Cell 2011; 41: 298-310.
39. Braddock DT, Louis JM, Baber JL, Levens D, Clore GM. Structure and dynamics of KH domains from FBP bound to single-stranded DNA. Nature 2002; 415: 1051-1056.
40. Benjamin LR, Chung HJ, Sanford S, Kouzine F, Liu J, Levens D. Hierarchical mechanisms build the DNA-binding specificity of FUSE binding protein. Proc Natl Acad Sci USA 2008; 105: 18296-18301.
41. Liu J, He L, Collins I, Ge H, Libutti D, Li J et al. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol Cell 2000; 5: 331-341.
42. Corsini L, Hothorn M, Stier G, Rybin V, Scheffzek K, Gibson TJ et al. Dimerization and protein binding specificity of the U2AF homology motif of the splicing factor Puf60. J Biol Chem 2009; 284: 630-639.
43. Page-McCaw PS, Amonlirdviman K, Sharp PA. PUF60: a novel U2AF65-related splicing activity. RNA 1999; 5: 1548-1560.
44. Chung HJ, Liu J, Dundr M, Nie Z, Sanford S, Levens D. FBPs are calibrated molecular tools to adjust gene expression. Mol Cell Biol 2006; 26: 6584-6597.
45. Hsiao HH, Nath A, Lin CY, Folta-Stogniew EJ, Rhoades E, Braddock DT. Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 2010; 49: 4620-4634.
46. Weber A, Liu J, Collins I, Levens D. TFIIH operates through an expanded proximal promoter to fine-tune c-myc expression. Mol Cell Biol 2005; 25: 147-161.
47. Bazar L, Meighen D, Harris V, Duncan R, Levens D, Avigan M. Targeted melting and binding of a DNA regulatory element by a transactivator of c-myc. J Biol Chem 1995; 270: 8241-8248.
48. Krumm A, Meulia T, Brunvand M, Groudine M. The block to transcriptional elongation within the human c-myc gene is determined in the promoter-proximal region. Genes Dev 1992; 6: 2201-2213.
49. Levens D. How the c-myc promoter works and why it sometimes does not. J Natl Cancer Inst Monogr 2008; 41-43.
50. Liu J, Chung HJ, Vogt M, Jin Y, Malide D, He L et al. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J 2011; 30: 846-858.
51. Kusik BW, Hammond DR, Udvadia AJ. Transcriptional regulatory regions of gap43 needed in developing and regenerating retinal ganglion cells. Dev Dyn 2010; 239: 482-495.
52. Nishizawa K, Okamoto H. Mutation analysis of the role for the carboxy-terminus encoding region in NGF-induced stabilization of GAP-43 mRNA. Biochem Biophys Res Commun 1994; 205: 1380-1385.
53. Wang W, Furneaux H, Cheng H, Caldwell MC, Hutter D, Liu Y et al. HuR regulates p21 mRNA stabilization by UV light. Mol Cell Biol 2000; 20: 760-769.
54. Dean JL, Sully G, Clark AR, Saklatvala J. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004; 16: 1113-1121.
55. Sully G, Dean JL, Wait R, Rawlinson L, Santalucia T, Saklatvala J et al. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1). Biochem J 2004; 377: 629-639.
56. Colombo E, Alcalay M, Pelicci PG. Nucleophosmin and its complex network: a possible therapeutic target in hematological diseases. Oncogene 2011; 30: 2595-2609.
57. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-153.
58. Sportoletti P, Grisendi S, Majid SM, Cheng K, Clohessy JG, Viale A et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008; 111: 3859-3862.
59. Zhang Z, Harris D, Pandey VN. The FUSE binding protein is a cellular factor required for efficient replication of hepatitis C virus. J Virol 2008; 82: 5761-5773.
60. Jang M, Park BC, Kang S, Chi SW, Cho S, Chung SJ et al. Far upstream element-binding protein-1, a novel caspase substrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene 2009; 28: 1529-1536.
61. Huang PN, Lin JY, Locker N, Kung YA, Hung CT, Huang HI et al. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res 2011; 39: 16.
62. Balvay L, Soto RR, Ricci EP, Decimo D, Ohlmann T. Structural and functional diversity of viral IRESes. Biochim Biophys Acta 2009; 1789: 542-557.
63. He L, Weber A, Levens D. Nuclear targeting determinants of the far upstream element binding protein, a c-myc transcription factor. Nucleic Acids Res 2000; 28: 4558-4565.
64. Fukumoto M, Sekimoto T, Yoneda Y. Proteomic analysis of importin alpha-interacting proteins in adult mouse brain. Cell Struct Funct 2011; 36: 57-67.
65. Buchan JR, Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol Cell 2009; 36: 932-941.
66. Thiede B, Dimmler C, Siejak F, Rudel T. Predominant identification of RNA-binding proteins in Fas-induced apoptosis by proteome analysis. J Biol Chem 2001; 276: 26044-26050.
67. Milosevic J, Bulau P, Mortz E, Eickelberg O. Subcellular fractionation of TGF-beta1-stimulated lung epithelial cells: a novel proteomic approach for identifying signaling intermediates. Proteomics 2009; 9: 1230-1240.
68. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J 1996; 15: 658-664.
69. Lasserre JP, Fack F, Revets D, Planchon S, Renaut J, Hoffmann L et al. Effects of the endocrine disruptors atrazine and PCB 153 on the protein expression of MCF-7 human cells. J Proteome Res 2009; 8: 5485-5496.
70. Felty Q. Proteomic 2D DIGE profiling of human vascular endothelial cells exposed to environmentally relevant concentration of endocrine disruptor PCB153 and physiological concentration of 17beta-estradiol. Cell Biol Toxicol 2011; 27: 49-68.
71. Nicolaides NC, Kinzler KW, Vogelstein B. Analysis of the 5' region of PMS2 reveals heterogeneous transcripts and a novel overlapping gene. Genomics 1995; 29: 329-334.
72. Quevillon S, Robinson JC, Berthonneau E, Siatecka M, Mirande M. Macromolecular assemblage of aminoacyl-tRNA synthetases: identification of protein-protein interactions and characterization of a core protein. J Mol Biol 1999; 285: 183-195.
73. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M et al. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 2000; 60: 5922-5928.
74. Ko HS, Kim SW, Sriram SR, Dawson VL, Dawson TM. Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 2006; 281: 16193-16196.
75. Atanassov BS, Dent SY. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep 2011; 12: 924-930.
76. Weber A, Kristiansen I, Johannsen M, Oelrich B, Scholmann K, Gunia S et al. The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 2008; 8: 369.
77. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M et al. Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 2009; 69: 2234-2243.
78. Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 2005; 5: 564-573.
79. Man TK, Lu XY, Jaeweon K, Perlaky L, Harris CP, Shah S et al. Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma. BMC Cancer 2004; 4: 45.
80. Engidawork E, Afjehi-Sadat L, Yang JW, Slavc I, Lubec G. Protein chemical identification and characterization of the human variants of far upstream element binding protein in medulloblastoma DAOY cell line. Int J Oncol 2006; 29: 721-736.
81. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
82. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery DM. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 2009; 28: 2485-2491.
83. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and-Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 1999; 19: 4672-4683.
84. Dang CV, ODonnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. Semin Cancer Biol 2006; 16: 253-264.
85. Abbas T, Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 2009; 9: 400-414.
86. Xiao J, Zhang Z, Chen GG, Zhang M, Ding Y, Fu J et al. Nucleophosmin/B23 interacts with p21WAF1/CIP1 and contributes to its stability. Cell Cycle 2009; 8: 889-895.
87. Colombo E, Bonetti P, Lazzerini Denchi E, Martinelli P, Zamponi R, Marine JC et al. Nucleophosmin is required for DNA integrity and p19Arf protein stability. Mol Cell Biol 2005; 25: 8874-8886.
88. Kuo ML, den Besten W, Bertwistle D, Roussel MF, Sherr CJ. N-terminal poly-ubiquitination and degradation of the Arf tumor suppressor. Genes Dev 2004; 18: 1862-1874.
89. Millard SS, Yan JS, Nguyen H, Pagano M, Kiyokawa H, Koff A. Enhanced ribosomal association of p27(Kip1) mRNA is a mechanism contributing to accumulation during growth arrest. J Biol Chem 1997; 272: 7093-7098.
90. Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN et al. MYC regulation of a 'poor-prognosis' metastatic cancer cell state. Proc Natl Acad Sci USA 2010; 107: 3698-3703.
91. Wolfer A, Ramaswamy S. MYC and metastasis. Cancer Res 2011; 71: 2034-2037.
92. Yan S, Zhou C, Lou X, Xiao Z, Zhu H, Wang Q et al. PTTG overexpression promotes lymph node metastasis in human esophageal squamous cell carcinoma. Cancer Res 2009; 69: 3283-3290.
93. Smith AP, Verrecchia A, Faga G, Doni M, Perna D, Martinato F et al. A positive role for Myc in TGFbeta-induced Snail transcription and epithelial-to-mesenchymal transition. Oncogene 2009; 28: 422-430.
94. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428.
95. Karst AM, Levanon K, Duraisamy S, Liu JF, Hirsch MS, Hecht JL et al. Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas. Gynecol Oncol 2011; 123: 8.
96. Rana S, Maples PB, Senzer N, Nemunaitis J. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008; 8: 1461-1470.
97. Xu SG, Yan PJ, Shao ZM. Differential proteomic analysis of a highly metastatic variant of human breast cancer cells using two-dimensional differential gel electrophoresis. J Cancer Res Clin Oncol 2010; 136: 1545-1556.
98. Huth JR, Yu L, Collins I, Mack J, Mendoza R, Isaac B et al. NMR-driven discovery of benzoylanthranilic acid inhibitors of far upstream element binding protein binding to the human oncogene c-myc promoter. J Med Chem 2004; 47: 4851-4857.
99. Stoneley M, Willis AE. Cellular internal ribosome entry segments: structures, trans-acting factors and regulation of gene expression. Oncogene 2004; 23: 3200-3207.